Details for Patent: 6,531,139

Title:	Self-emulsifying formulation for lipophilic compounds
Abstract:	The present invention provides a novel pharmaceutical composition based on the use of a particular oil phase which comprises a lipophilic, pharmaceutically active agent, a mixture of diglyceride and monoglyceride in a ratio of from about 9:1 to about 6:4 by weight (diglyceride:monoglyceride) wherein the diglyceride and monoglyceride are mono- or di- unsaturated fatty acid esters of glycerol having sixteen to twenty-two carbon chain length, one or more pharmaceutically acceptable solvents, and one or more pharmaceutically acceptable surfactants. The composition is in a form of self-emulsifying formulation which provides high concentration and high oral bioavailability for lipophilic compounds.
Inventor(s):	Gao; Ping (Portage, MI), Morozowich; Walter (Kalamazoo, MI)
Assignee:	Pharmacia & Upjohn Company (Kalamazoo, MI)
Filing Date:	Jul 27, 1998
Application Number:	09/122,926
Claims:	1. A pharmaceutical composition comprising; (a) a lipophilic, pharmaceutically active agent, (b) a mixture consisting essentially of diglyceride and monoglyceride in a ratio of from about 9:1 to about 6:4 by weight (diglyceride:monoglyceride) wherein the diglyceride and monoglyceride are mono- or di-unsaturated tatty acid esters of glycerol having sixteen to twenty-two carbon chain length, (c) one or more pharmaceutically acceptable solvents, and (d) one or more pharmaceutically acceptable surfactants; wherein the solvent is propylene glycol, polypropylene glycol, polyethylene glycol, glycerol, ethanol, dimethyl isosorbide, glycofurol, propylene carbonate, dimethyl acetamide, or a mixture thereof; wherein said surfactant is Polyoxyl 40 hydrogenated castor oil, Polyoxyl 35 castor oil, polyethylene glycol 12-hydroxy stearate, polyoxyethylene glyceryl trioleate, Peglicol 6-oleate, Polyoxyethylene stearates, Poloxamers, Polysorbates, or Saturated Polyglycolyzed Glycerides; with the proviso that said lipophilic, pharmaceutically active agent has a LOG P value .gtoreq.2, an intrinsic aqueous solubility .ltoreq.0.1 in the pH range of 1 to 8 and a solubility greater than 1 mg/ml in the mixture of b, c and d as defined herein. 2. The pharmaceutical composition of claim 1 wherein the lipophilic, pharmaceutically active agent is selected from the group consisting of Medroxyprogesterone Acetate, Progesterone, Testosterone, Troglitazone, Pioglitazone, Glyburide, Ketoconazole, Itraconazole, Camptothecin, (4S)4,11-diethyl-4,9-dihydroxy-1H-pyrano[3',4': 6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, Irinotecan hydrochloride, Paclitaxel, Docetaxel, 2aR-[2a.alpha.,4a.beta.,6.beta.,7.beta.,9(.alpha.R*,.beta.S*),11.alpha.,12 .alpha.,12a.alpha.,12b.alpha.]]-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,4a, 5,6,7,10,11,12, 12a, 12b-decahydro-11-hydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cycl odeca[3,4]benz[1,2-b]oxet-9-yl .beta.-[[[(1,1-dimethylethyl)amino]carbonyl] amino]-.alpha.-hydroxy benzenepropanoate, (1S,2S,3R,4S,7R,10R,12R)-4,12-bis(acetyloxy)-15-[((2R,3S)-3-{[(tert-butyla mino)carbonyl]amino}-2-hydroxy-3-phenylpropanoyl)oxy]-1-hydroxy-10,14,17,17 -tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.0.sup.3.10.0.sup.4.7 ]heptadeca-8,14-dien-2-yl benzoate, PGE.sub.2.alpha., PGE.sub.1, PGE.sub.2, Delavirdine mesylate, Vitamin E, Tirilazad Mesylate, Griseofulvin, Phenytoin, Ibuprofen, Flurbiprofen, 1-[(2,4-di(1-pyrrolidinyl)-9H-pyrimido[4,5-b]-yl]indol-9-ylacetyl]-1-(1-py rrolidine, 2-[2,4-di(1-pyrrolidinyl)-9H-pyrimido[4,5-b]indol-9-yl]-1-(1-pyrrolidinyl) -1-ethanone, (S)-1-[2-[4-[4-(aminocarbonyl)phenyl]-1-piperazinyl]ethyl]-3,4-dihydro-N-m ethyl-1H-2-benzopyran-6-carboxamide, 1H-2-benzopyran-6-carboxamide, 1-[2-[4-[4-(aminocarbonyl)phenyl]-1-piperazinyl]ethyl]-3,4-dihydro-N-methy l-, (S)- or (1S)-1-(2-{4-[4-(aminocarbonyl)phenyl]-1-piperazinyl}ethyl)-N-methyl-3,4-d ihydro-1H-isochromene-6-carboxamide, (-)-6-chloro-2-[(1-furo[2,3-c]pyridin-5-ylethyl)thio]-4-pyrimidinamine, and 6-chloro-2-{[(1S)-1-furo[2,3-c]pyridin-5-ylethyl]sulfonyl}-4-pyrimidinylam ine. 3. The pharmaceutical composition of claim 1 wherein the lipophilic, pharmaceutically active agent is Irinotecan hydrochloride. 4. The pharmaceutical composition of claim 1 wherein the lipophilic, pharmaceutically active agent is in an amount of from about 1% to about 40% by weight of the total composition. 5. The pharmaceutical composition of claim 1 wherein the lipophilic, pharmaceutically active agent is in an amount of from about 5% to about 30% by weight of the total composition. 6. The pharmaceutical composition of claim 1 wherein said diglyceride is diolein, dilinoleate or a mixture thereof. 7. The pharmaceutical composition of claim 1 wherein said diglyceride is diolein. 8. The pharmaceutical composition of claim 1 wherein said monoglyceride is monoolein, monolinoleate or a mixture thereof. 9. The pharmaceutical composition of claim 1 wherein said monoglyceride is monoolein. 10. The pharmaceutical composition of claim 1 wherein the mixture of diglyceride and monoglyceride is in an amount of from about 5% to about 40% by weight of the total composition. 11. The pharmaceutical composition of claim 1 wherein the mixture of diglyceride and monoglyceride is in an amount of from about 5% to about 35% by weight of the total composition. 12. The pharmaceutical composition of claim 1 wherein the mixture of diglyceride and monoglyceride is in a ratio of about 8:2 by weight (diglyceride:monoglyceride). 13. The pharmaceutical composition of claim 1 wherein the mixture of diglyceride and monoglyceride is in a ratio of about 9:1 by weight (diglyceride:monoglyceride). 14. The pharmaceutical composition of claim 1 wherein the pharmaceutically acceptable solvent is propylene glycol. 15. The pharmaceutical composition of claim 1 wherein the pharmaceutically acceptable solvent is a mixture comprising propylene glycol and 95% (v/v) ethanol in a ratio of about 1:1. 16. The pharmaceutical composition of claim 1 wherein the pharmaceutically acceptable solvent is in an amount of from about 10% to about 30% by weight of the total composition. 17. The pharmaceutical composition of claim 1 wherein the pharmaceutically acceptable solvent is in an amount of from about 15% to about 25% by weight of the total composition. 18. The pharmaceutical composition of claim 1 wherein the pharmaceutically acceptable surfactant is Polyoxyl 40 hydrogenated castor oil or Polyoxyl 35 castor oil. 19. The pharmaceutical composition of claim 1 wherein the surfactant is in an amount of from about 10% to about 50% by weight of the total composition. 20. The pharmaceutical composition of claim 1 wherein the surfactant is in an amount of from about 30% to about 45% by weight of the total composition. 21. The pharmaceutical composition of claim 1 wherein the composition further comprises an amine. 22. The pharmaceutical composition of claim 21 wherein the amine is lower alkylamine, basic amino acid or choline hydroxide. 23. The pharmaceutical composition of claim 22 wherein the lower alkylamine is ethanolamine, diethanolamine, triethanolamine, ethylenediamine, dimethylaminoethanol or tris(hydroxymethyl)aminomethane. 24. The pharmaceutical composition of claim 22 wherein the basic amino acid is arginine, lysine or guanidine. 25. The pharmaceutical composition of claim 21 wherein the amine is in an amount from about 0.1% to about 10% by weight of the total composition. 26. A self-emulsifying formulation vehicle comprising a mixture consisting essentially of diglyceride and monoglyceride in a ratio of from about 9:1 to about 6:4 by weight (diglyceride:monoglyceride) wherein the diglyceride and monoglyceride are mono- or di- unsaturated fatty acid esters of glycerol having sixteen to twenty-two carbon chain length, one or more pharmaceutically acceptable solvents, and one or more pharmaceutically acceptable surfactants; wherein the solvent is propylene glycol, polypropylene glycol, polyethylene glycol, glycerol, ethanol, dimethyl isosorbide, glycofurol, propylene carbonate, dimethyl acetamide, or a mixture thereof; wherein said surfactant is Polyoxyl 40 hydrogenated castor oil, Polyoxyl 35 castor oil, polyethylene glycol 12-hydroxy stearate, polyoxyethylene glyceryl trioleate, Peglicol 6-oleate, Polyoxyethylene stearates, Poloxamers, Polysorbates, or Saturated Polyglycolyzed Glycerides. 27. The self-emulsifying formulation vehicle of claim 26 further comprising an amine. 28. The self-emulsifying formulation vehicle of claim 26 wherein said diglyceride is diolein, dilinoleate or a mixture thereof. 29. The self-emulsifying formulation vehicle of claim 26 wherein said diglyceride is diolein. 30. The self-emulsifying formulation vehicle of claim 26 wherein said monoglyceride is monoolein, monoolinoleate or a mixture thereof. 31. The self-emulsifying formulation vehicle of claim 26 wherein said monoglyceride is monoolein. 32. The self-emulsifying formulation vehicle of claim 26 wherein the mixture of diglyceride and monoglyceride is in a ratio of about 7:3 by weight diglyceride:monoglyceride). 33. The self-emulsifying formulation vehicle of claim 26 wherein the mixture of diglyceride and monoglyceride is in a ratio of about 8:2 by weight (diglyceride:monoglyceride). 34. The self-emulsifying formulation vehicle of claim 26 wherein the mixture of diglyceride and monoglyceride is in a ratio of about 9:1 by weight diglyceride:monoglyceride). 35. A pharmaceutical composition according to claim 1, wherein the mixture of diglyceride and monoglyceride is prepared by mixing diglyceride and monoglyceride in appropriate relative proportion. 36. A self-emulsifying formulation vehicle according to claim 26, wherein the mixture of diglyceride and monoglyceride is prepared by mixing diglyceride and monoglyceride in appropriate relative proportion. 37. A pharmaceutical composition according to claim 1, wherein the composition is capable of forming a microemulsion upon mixing with water. 38. A pharmaceutical composition according to claim 37, wherein the microemulsion formed has an almost transparent or translucent appearance and the average particle (droplet) size of the emulsion is less than 150 nanometers (0.15 microns). 39. A pharmaceutical composition comprising: (a) a lipophilic, pharmaceutically active agent; (b) a mixture consisting of diolein and monoolein in a ratio of about 9:1 to about 8:2 by weight; (c) a solvent comprising propylene glycol or a mixture of propylene glycol and ethanol in an amount of from about 15% to about 25% by weight of the total composition; (d) a surfactant comprising glycerol polyethylene glycol oxystearate or glycerol polyethylene glycol ricinoleate in an amount of from about 30% to about 45% by weight of the total composition; and optionally a basic amine in an amount of about 0.1% to about 7% of the total composition; and wherein the lipophilic active agent has a LOG P value .gtoreq.2, an intrinsic aqueous solubility .ltoreq.0.1 mg/ml in the pH range of 1 to 8, and a solubility greater than 1 mg/ml in the mixture of b, c and d as defined herein.